Table 1 Patient and tumor characteristics
Variable | n. (%) or median (range) | |
|---|---|---|
No. of patients | 34 (100) | |
No. of tumors | 45 (100) | |
Gender | male/female | 29 (85.3)/5 (14.7) |
Age, years | 65 (41–85) | |
Viral hepatitis | HBV | 17 (50.0) |
HCV | 6 (17.6) | |
both | 2 (5.9) | |
none | 9 (26.5) | |
Recurrent HCC | yes/no | 25 (73.5)/9 (26.5) |
Tumor size, cm* | 3.9 (0.8–22) | |
Portal vein tumor thrombosis | present/absent present/absent* | 10 (29.4)/24 (70.6) 10 (22.2)/35 (77.8) |
Extrahepatic spread | present/absent | 6 (17.6)/28 (82.4) |
ECOG performance status | 0 | 15 (44.1) |
1 | 15 (44.1) | |
2 | 4 (11.8) | |
AFP level, ng/ml | <200/≥200 | 24 (70.6)/10 (29.4) |
CTP class | A/B | 26 (76.5)/8 (23.5) |
BCLC stage | A/B/C | 9 (26.5)/3 (8.8)/22 (64.7) |
Previous treatment | Surgery | 9 (26.5) |
RFA | 8 (23.5) | |
TACE | 16 (47.1) | |
SABR | 3 (8.8) | |
Sorafenib | 3 (8.8) | |
Naïve | 9 (26.5) | |
SABR regimen* | ||
total dose, Gy | 45 (30–60) | |
fraction number | 5 (4–6) | |
EQD2, Gy | 71.3 (40–125) |
